Molecular Cancer Therapeutics with Dr. Louis Denis
Moderated by: Richard Davis, PhD
Molecular Cancer Therapeutics Associate Editor
Watch the recording of the AACR Journal Club session featuring Dr. Louis Denis discussing his First Disclosure article published in Molecular Cancer Therapeutics, "ASN004, a 5T4-targeting scFv-Fc antibody-drug conjugate with high drug-to-antibody ratio, induces complete and durable tumor regressions in preclinical models." In the paper, Dr. Denis and colleagues present the preclinical development and profile of ASN004, a 5T4-targeted antibody drug conjugate (ADC) that incorporates a novel single-chain scFv-Fc antibody and Dolaflexin drug-linker technology, with an Auristatin F Hydroxypropylamide payload drug-to-antibody ratio of ca. 10-12. The pharmacology, toxicology and pharmacokinetic properties of ASN004 and its components were investigated in vitro and in vivo and clinical development is planned in patients with advanced solid tumors.
Stay tuned for the Q&A session at the end of the recording.
About the Featured Speaker:
Louis Denis, MD is Chief Medical Officer at Asana BioSciences, a clinical stage biopharmaceutical company focused on discovery and development of novel targeted investigational medicines in oncology and immunology/inflammation.